{"entity":{"id":"nct05136326","kind":"trial","name":"Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer","aka":["CATARTIC"],"tldr":"A phase 2 trial of capecitabine and temozolomide in colorectal cancer, run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, now recruiting.","summary":"Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer is a phase 2, interventional study registered as NCT05136326 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, with a registry enrolment figure of 21 participants, started 2021-12-01 and due to reach its primary completion in 2023-12. Interventions recorded: External-beam radiation; Capecitabine; Temozolomide. Conditions listed: Rectal Cancer. Primary outcome: To evaluate the rate of complete pathologic response (pCR). Colorectal eligibility wording from the registry: \"* Histologically confirmed diagnosis of rectal adenocarcinoma, with centrally confirmed mismatch repair proficiency (MSS) by PCR, lack of MGMT expression by IHC and MGMT promoter methylation by pyrosequencing;\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05136326","url":"https://clinicaltrials.gov/study/NCT05136326"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["capecitabine","temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05136326","phase":"2","setting":"Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05136326/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}